November 2023 – OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas

November 2023 – OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research & Development

November 2023 – OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting

October 2023 – OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

September 2023 – OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study

May 2023 – OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation at 2023 ASCO Annual Meeting

April 2023 – OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

April 2023 – OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR Annual Meeting 2023

March 2023 – OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

March 2023 – OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023

January 2023 – OncoNano Medicine’s Pegsitacianine Granted Breakthrough Therapy Designation for Real-Time Surgical Imaging by the Food and Drug Administration

November 2022 – OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 2022 – OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 2022 – OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting

September 2022 – OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference

September 2022 – OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022

June 2022 – OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer

May 2022 – OncoNano Medicine Announces the Appointment of Elina Lavit as Vice President, Business Development

April 2022 – OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting

April 2022 – OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting

March 2022 – OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

December 2021 – OncoNano Medicine Appoints Brett Giroir, M.D., to Board of Directors

October 2021 – $18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas

October 2021 – Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study

October 2021 – Positive Preclinical Data for ONM-501 at AACR Virtual Conference

September 2021 – Present at The American Association for Cancer Research Virtual Conference

September 2021 – OncoNano Medicine Announces Expanded Research Collaboration with UT Southwestern Medical Center to Advance Development of New Cancer Therapies

September 2021 – OncoNano Medicine to Present at The World Molecular Imaging Congress

July 2021 – OncoNano Medicine to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

June 2021 – OncoNano Medicine Raises ~$50 Million in Series B Financing

March 2021 –OncoNano Awarded $15.4 Million Grant

March 2021 –Publication of ONM-100 Phase 1

February 2021 – Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer

February 2021 – OncoNano Medicine Announces Martin Driscoll as Chief Executive Officer

November 2020 – OncoNano Announces Positive Preclinical Data for ONM-400 Tumor Specific IL-2 Delivery at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 2020 – OncoNano Announces Positive Clinical Data for Cancer Imaging Agent ONM-100 at The World Molecular Imaging Congress

August 2020 – OncoNano Awarded $9.97 Million Grant from Cancer Prevention and Research Institute of Texas

June 2020 – OncoNano Announces Publication of ONM-100 Phase 1 Data in Nature Communications

November 2019 – OncoNano Announces Presentations at the 2019 SITC Annual Meeting

September 2019 – ONM-100 to be Featured in Presentation at World Molecular Imaging Congress 2019 

August 2019 – OncoNano Awarded $15.4 Million Grant from Cancer Prevention and Research Institute of Texas

July 2019 – OncoNano Closes Additional $23.7 Million in Second Tranche of Series A Financing, Bringing Total Series A Raise to $35.4 Million

May 2019 – OncoNano to Present Poster on First-in-Human Study of pH-Activated Platform for Detection of Solid Tumors During Surgery at 2019 ASCO Annual Meeting

January 2019 – OncoNano Receives Authorization to Proceed from FDA for IND Application and Fast Track Designation for ONM-100, Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

December 2018 – OncoNano Announces Completion of Phase 1a Study and Expands into Phase 1b for Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

July 2018 – OncoNano Announces Dosing of Patients in Phase 1 Clinical Trial with ONM-100, an Intraoperative Imaging Agent that Targets Tumor Acidosis for the Detection of Solid Tumors

May 2018 – OncoNano Announces $11.7 Million Series A Financing to Support Development of pH-activated Compound Platform for Disease Detection and Treatment